edical or veterinary science and hygiene (A61)

A   Human necessities(308424)
A61            edical or veterinary science; hygiene(132510)

Salts and crystalline forms of apottosis-inducing agent // 2628560
FIELD: pharmacology.SUBSTANCE: invention relates to a compound having the systematic name 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl]methyl}piperazin-1-yl)-N-({3-nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridin-5-yloxy) benzamide (compound 1) in the form of a free base crystalline anhydrate, a free base hydrate of crystalline form, a solvate of crystalline form, a hydrochloride salt of crystalline form, or a sulfate salt of crystalline form. The invention also relates to a pharmaceutical composition having an inhibitory activity against anti-apoptotic proteins of the Bcl-2 family comprising a therapeutically effective amount of the compound of the invention and one or more pharmaceutically acceptable excipients.EFFECT: crystalline forms of compound 1 suitable for use as an active pharmaceutical ingredient.21 cl, 14 dwg, 14 tbl, 17 ex
Oral care products, including zinc oxide and trimethylglycine // 2628540
FIELD: pharmacology.SUBSTANCE: group of inventions refers to oral care compositions, consisting of a mixture of zinc oxide and trimethylglycine (TMG), where the TMG is included into the composition in the form of hydrohalogenide, and zinc oxide and TMG form soluble complexes, selected from zinc-TMG-hydrohalogenide complexes, zinc-hydrohalogenide complexes and mixtures, where the hydrohalogenide is selected from hydrofluoride, hydrochloride and hydrobromide, as well as to a method for tooth enamel erosion treatment or mitigation, biofilm and bacterial plaque reduction, gingivitis reduction, tooth decay and cavities formation reduction, dentin hypersensitivity reduction, including application of such composition to the teeth, zinc oxide application together with the TMG in the form of hydrohalogenide during oral care composition production.EFFECT: creation of a complex, capable of yielding a solution which precipitates when diluted.15 cl, 4 ex, 6 tbl

Antimicrobial compositions of wide spectrum of action based on taurolidine and protamine combininations and medical devices containing such compositions // 2628539
FIELD: pharmacology.SUBSTANCE: group of inventions designed for antimicrobial treatment of implantable medical devices. The antimicrobial composition for antimicrobial coating application to medical devices contains about 50 to 99 wt % of taurolidine and about 1 to 50 wt % of protamine. For medical device coating, a medical device with at least one surface is provided and at least a portion of the said antimicrobial coating is applied to the surface. Polymeric resin which comprises the said composition is also provided for the manufacture of medical devices.EFFECT: antimicrobial composition effective against a wide range of microbes.80 cl, 2 dwg, 3 tbl, 4 ex

Composition including amlodipine and losartan having improved stability // 2628538
FIELD: pharmacology.SUBSTANCE: pharmaceutical composition for cardiovascular disorders prevention and treatment is described. The said composition comprises amlodipine besylate in an amount of 1.7 to 1.72 wt %, potassium losartan in an amount of 12.22 to 12.37 wt %, and propyl gallate in an amount of 0.01 wt %, based on the total weight of the composition. The said composition has the form of a two-layer pill having two separate layers consisting of an amlodipine layer containing amlodipine besylate and propyl gallate and a layer of losartan containing potassium losartan.EFFECT: improved composition stability in combination with simplicity of preparation.6 cl, 21 tbl, 2 dwg, 5 ex
Treatment of coagulation disease by administration of recombinant vwf // 2628537
FIELD: medicine.SUBSTANCE: group of inventions relates to a method of treating von Willebrand's disease or hemophilia A in a patient in need of treatment comprising administering to the patient a recombinant vWF (vWF) factor so that the half-life of factor VIII is prolonged compared to a patient administered vWF derived from blood plasma, where pFB is not modified with an aqueous soluble polymer. In this case, the pFB is a composition of high molecular weight PV multimers containing at least 20% of the PV emperors or higher-order multimers, with the rVB having a higher specific activity than the vWF derived from the blood plasma. The group of inventions also relates to a method for treating hemophilia A or vWF in a patient in need of treatment that includes administering to the patient a recombinant vWF (vWF) factor, wherein the half-life of FVIII is at least 1.5 times higher than the half-life of FVIII in the patient being treated Von Willebrand factor derived from blood plasma.EFFECT: increase in the half-life of FVIII in the treatment of von Willebrand disease or haemophilia A in the subject.29 cl, 5 ex, 22 dwg, 34 tbl

Production and application of bacterial histamine // 2628536
FIELD: medicine.SUBSTANCE: method for selecting a probiotic lactic bacterial strain for use in the local production of histamine in a mammal is provided. A product and composition for the local production of histamine in a mammal containing a lactic acid bacterial strain having an active histidine operon and capable of producing histamine is proposed for use in the treatment and/or prevention of inflammatory conditions.EFFECT: local production of histamine in a mammal by selecting certain strains of lactic acid bacteria.13 cl, 9 dwg, 2 tbl, 5 ex
External application means for chronic dermatosis treatment, and method for its production // 2628535
FIELD: medicine.SUBSTANCE: invention can be used as a preventive and therapeutic agent with anti-inflammatory and antibacterial properties, intended for external use, for treatment of all kinds of chronic dermatoses: dermatitis, neurodermatitis, furunculosis, eczema, fungal diseases, parasitic skin diseases, acne, and method for its production. The external agent for treatment of chronic dermatitis in the form of an aqueous suspension of mercuric monochloride is prepared by a process comprising premixing of powdered mercury monochloride with nitric acid at the following ratio of components, wt %: mercury monochloride 0.3-0.6; nitric acid 0.6-1.0, at a temperature of 70-90°C, stirring for 1 hour. Then the obtained solution is mixed with water of high mineralization from the "Belaya Gorka" mineral source to 100 wt %. At that, the pH of the obtained suspension is adjusted to 1-2 with nitric acid.EFFECT: increased efficiency of treatment.2 cl, 7 ex

Composition containing buffered lactic acid // 2628534
FIELD: pharmacology.SUBSTANCE: group of inventions refers to medicine, specifically to lubricating compositions containing buffered lactic acid with pH in the range of 3.0 to 6.5. The composition has an aqueous activity of 0.10 to 0.50 and the predetermined aqueous activity is obtained by drying.EFFECT: when the absorbent article contacts the skin or mucous membrane of the user, the friction between the absorbent article and the skin or mucosa decreases, the composition has a pH value in the range corresponding to acids that is close to the pH of skin or mucous membrane.13 cl, 9 dwg, 3 tbl, 1 ex
Anti-cellulite gel // 2628533
FIELD: cosmetology.SUBSTANCE: gel further contains pectin, hydrogenated castor oil, wheat germ oil, ginger essential oil, chlorella, propylene glycol extract of juniper, propylene glycol extract of horsetail, propylene glycol extract of horse chestnut, glycerin, preservative and water, the agent components are in a certain ratio, in wt %.EFFECT: increased tone and strengthening of blood vessel walls, lipid metabolism stimulation, surface smoothing, increased skin resilience and elasticity, cellulite elimination.1 tbl

Surgery guide, appropriate for patient and method for its application // 2628464
FIELD: medicine.SUBSTANCE: device is adapted to interface with an anatomical feature of a particular vertebra of a patient and comprises a medial body positioned adjacent to the vertebra and having a proximal end and a distal end, the first guide selectively attached to the medial body. The first guide has the first distal surface that is anatomically mated to at least one first contour of the said particular vertebra when the first guide is attached to the medial body, the second guide is selectively attached to the medial body. The second guide has a second distal surface that is anatomically mated to at least one second contour of the said particular vertebra when the second guide is attached to the medial body, wherein the first and the second distal surfaces are defined from the patient's anatomy and are complementary thereto.EFFECT: use of the invention allows to increase the safety and effectiveness of the surgical procedure completion.18 cl, 43 dwg

ethod for information processing // 2628463
FIELD: medicine.SUBSTANCE: devices and a method are provided comprising a contact lens that facilitates collection and/or processing of information related to the measured features. In one aspect, the system may comprise a contact lens with an analyte component. The contact lens may include: a substrate; and a circuit located on or in the substrate. The circuit may include: a plurality of sensors configured to measure corresponding features associated with the contact lens carrier; and a communication component configured to transmit information indicating the measured features. The analytical component can be configured to: receive information indicating the measured features; and generating statistical information based on at least information indicating the measured features.EFFECT: extended range of technical means.13 cl, 9 dwg

System of lenses for presbyopes with different eye vision // 2628462
FIELD: medicine.SUBSTANCE: set of lenses for patients with presbyopia with different eyesight contains: a selection guide with lens design and additional optical power options and a group of lenses having a variety of designs, each having its own refractive power. In such a system, for each lens design and selection specified in the guide, the visual inconsistency of is within the range specified by unequations >0.2*add. power + 0.2 and <0.7*add. power + 0.5. The value of additional power is less than or equal to 1. A method for creation of a set of contact lenses for patients with presbyopia with different eye vision contains the following stages: creation of a guide for selection with lenses optical power and required additional power; establishment of an evaluation function, which provides measurement of binocular vision at a great distance, middle distance and near in the entire range of additional power specified in the guide; and application of optimisation to establish lens design and modification of the selection guide that reduce the overall assessment function of the system.EFFECT: application of this group will improve visual effectiveness.13 cl, 16 dwg, 6 tbl, 4 ex

Ultrasonic tip // 2628461
FIELD: medicine.SUBSTANCE: tip system comprises: an ultrasonic tip that includes a vibration source configured to generate a plurality of ultrasonic vibrations, and a sound receiver configured to convert vibrations to ultrasonic motion; and a blade connected to the sound receiver and made to move under the influence of ultrasonic movements. The blade has a blade handle with a central axis and a razorblade. The blade has a proximal portion extending from the distal end of the blade handle, and a tip extending from the distal end of the proximal portion. The central axis of the proximal portion has a non-zero bending angle θ, the value of which is greater than 0 and less than 30 degrees relative to the central axis of the blade handle; and the tip central axis is located at an angle of the θ razor blade, from 20 to 60 degrees relative to the central axis of the blade handle.EFFECT: use of this invention allows membrane separation during surgery of a patient with retinopathy.11 cl, 4 dwg

ethod for transposition of lower-polar aberrated kidney vessel in case of hydronephrosis // 2628460
FIELD: medicine.SUBSTANCE: transposition of the lower polar aberrated kidney vessel during hydronephrosis is performed by a flap from the parietal peritoneum of the abdominal cavity lateral canal. A flap on the feeding leg is directed under the aberrated lower-polar vessel and the vessel is moves upwards by pulling from the ureterocutaneous segment. The stretched flap is fixed by the fibrous capsule of the kidney to its front surface.EFFECT: method allows to exclude microcirculation disorders in the kidney capsule and cortical layer, as well as massive cicatricial process in the perirenal space.5 dwg

New pyrimidine inhibitors of human adenovirus replication // 2628456
FIELD: pharmacology.SUBSTANCE: invention relates to new 5-aminouracil derivatives containing 4-(phenoxy) benzyl or ω-(phenoxy)alkyl substituent in the N1 position, corresponding to the general structural formula (I). Compounds represent a new class of anti-adenoviral agents of a non-nucleoside nature. In the general formula (I), X = CH or N; Y=(CH2)2, (CH2)3, (CH2)4 or C6H4; R1= H, R2= C6H or 3,5-Cl2C6H3; R1+R2= morpholino; R3=H, F or Cl.EFFECT: compounds have a selective antiviral effect against human adenoviruses and can be used for treatment of adenoviral infections.1 dwg, 3 tbl, 11 ex
ethod for heterotopic ossification surgical treatment with local neural simulation of spastic syndrome // 2628370
FIELD: medicine.SUBSTANCE: for surgical treatment of heterotopic ossification with local neural simulation of the patient spastic syndrome, preliminary multilayer spiral computerized tomography (CT) is used to ptovide spatial imaging of bone structures and ossificates. The method of magnetic resonance imaging reveals the ossificate soft tissue component which is not visualized by MSCT. Then the heterotopic ossificate maturity stage is determine by calcium-phosphorus metabolism indices - alkaline phosphatase, osteocalcin, and bone matrix formation marker PINP - N-terminal pro-peptide of type 1 procollagen in patient's venous blood. If the measured parameters of N-terminal propeptide of type 1 procollagen - PINP are less than 76 ng/ml, even in case of an isolated lesion of one elbow or knee joint, alkaline phosphatase level is in the range 40-150 U/l and osteocalcin level is within 11-46 ng/mL, completion of osteoid formation and mineralization with formation and maturation of newly formed cancellous bone is concluded. In this case, surgical ossificates removal from the affected joint is prescribed. At that, local neural simulation of spastic syndrom is performed prior to surgical removal of ossificates, until it a stable decrease to the level of 0 to 1 on Ashworth scale is reached. Next, surgical treatment is performed involving ossificate resection or removal of an adequate volume of heterogeneous bone to restore the functionally adequate range of motion in the affected joint.EFFECT: possibility of surgical treatment of heterotopic ossification in patients with spastic syndrome, minimizing the risk of complications during surgical treatment, and pathological process recurrence.3 cl, 5 ex
ethod of multispiral computer tomography of slowly consolidated distraction regenerates of long bones of limbs // 2628369
FIELD: medicine.SUBSTANCE: invention relates to a method for multislice computed tomography of delayed consolidating distraction reductions (DCDR) of long limb bones (LLB) after repeated previous surgical interventions to compensate for the shortening of the patient's limb. Determining the spatial structure of the DCDR by performing 64 slices per revolution of the gantry with the cut thickness 0.625 mm, without tilting the gantry with a voltage of 120 kV, a current of 175 mA, in a time of 2.2 seconds at a pitch of 0.516:1. Using an overview transcript of 150-250 mm, multiplanar reconstruction of the image in two mutually perpendicular planes is performed - the frontal and sagittal planes, which reveal the localization, volume and character of the internal structure of the DCDR, as well as possible formed bone defects of the cortical layer of the DCDR. An evaluation of the stage of formation of the cortical layer of DCDR on axial sections is carried out by measuring the density along the perimeter of the patient's DCDR cortical layer in Hounsfield's unit (HU) and the density of the maternal bone in HU along its perimeter in its proximal and distal fragments adjacent to the DCDR. The value of the relative density is calculated - the ratio of the arithmetic mean density of the cortical layer of the patient DCDR to the index of the arithmetic mean density of its maternal bone in its proximal and distal sections adjacent to the DCDR. If the relative density is above 0.77, the fact of the passage of the natural consolidation of DCDR is established with sufficient metabolic maturity in the formation of compact bone tissue. At a value below 0.77, the fact of natural consolidation of DCDR with insufficient metabolic maturity is established, with a slow rate of formation of compact bone tissue.EFFECT: method provides an accurate definition of the localization, volume, nature of the internal structure of the distraction regenerate, possible formed bone defects of the cortical layer.2 cl, 3 ex
ethod for low invasive surgical stimulation of reparative osteogenesis of slowly consolidated distraction regenerates in combination with false connection of limbs long bones of limbs in case of soft scar tissues // 2628368
FIELD: medicine.SUBSTANCE: under the control of electron-optical transducer, a guiding drill rod is introduced through the slow-consolidating distraction regenerate area and the false joint area, through which a cutting tool in the form of a cannulated flexible shaft with a drill is then introduced, and a hole of a specified diameter is formed in the medullary canal of the long tubular bone using a replaceable cutting tools set with drills of increasing diameter. A nanostructured composite implant is inserted into the formed internal cavities through a hole of a predetermined diameter formed in the medullary canal of the long tubular bone in slowly consolidating distraction regenerate and the false joint area.EFFECT: method allows to reduce the time of distraction regenerate reconstruction into a full bone.2 cl
ethod for quantitative estimation of violations of right ventricle myocardium perfusion based on data of one-photon-emission computer tomography // 2628367
FIELD: medicine.SUBSTANCE: invention can be used to quantify the violations of right ventricular (RV) myocardial perfusion according to single-photon emission computed tomography (SPECT). Single-photon emission computed tomography (SPECT) is performed, and the ratio of the intensity radiopharmaceutical (RP) accumulation by the right and left ventricle (LV) is measured. At the same time, RV outflow is performed semi-automatically using the "restriction" and "masking" modes to obtain quantitative polar RV perfusion maps in addition to similar LV maps. Quantitative parameters of RV perfusion abnormalities are defined similar to LV, including data on absolute statistics of the account in each RV segment. Then the RV/LV(s) coefficient is calculated using the quantitative polar map data: RV/LV(s)=CmaxRV/CmaxLV, where Cmax RV, LV is the maximum value of the number of pulses in segments related to the RV and the LV, respectively. For RV/LV(s) values <0.3 the RV condition is interpreted as normal, the values of 0.3<RV/LV(s)<0.5 are interpreted as boundary values, RV/LV(s) values >0.5 are interpreted as signs of RV overload and hypertrophy.EFFECT: increased sensitivity, accuracy of quantification and diagnosis of violations of right ventricular myocardium perfusion, characterized by easy reproducibility and operational independence.4 dwg, 3 ex

Techniques and device for 3d biocompatible batteries production // 2628336
FIELD: electricity.SUBSTANCE: 3D biocompatible batteries production techniques and devise, which is made in line with the indicated method, are offered. The offered equipment functional area may involve different medical devices, for which batteries are obligatory elements, for example, in implantable devices. The conductor lines are shaped on the 3D surfaces in the 3D biocompatible batteries production technique. These surfaces comprise two or more unparalleled planes with the batteries active materials application on the conductor lines, and with the application of the battery acid on top of at a minimum anode and cathode part, succeeded by the anode, cathode and battery acid insaccation with the use of the biocompatible material.EFFECT: biocompatible battery safety, reliability, compactability, power capacity improving.20 cl, 5 dwg, 3 tbl

Combined vaccines for prevention of pigs viral infections // 2628313
FIELD: biotechnology.SUBSTANCE: inventions relate to vaccine compositions containing a vaccine against PRRSV (pig reproductive and respiratory syndrome virus) and the second vaccine against the pig virus that do not substantially interfere immunologically with each other. The vaccine against the second swine virus can be a vaccine against CSFV (classical swine fever virus) and/or PRV (pseudorabies virus). Methods for preparation of vaccines and formulations are also provided.EFFECT: vaccine compositions described herein impart protective immunity to pigs against reproductive and respiratory syndrome, classical swine fever and/or pseudorabism.44 cl, 40 dwg, 13 tbl, 25 ex

Antibacterial composition for prevention or treatment of hospital infections (versions), bacteriophage stamps used to obtain such composition // 2628312
FIELD: biotechnology.SUBSTANCE: composition includes 7 strains of bacteriophage, each represented by a combination of bacterial phagolysates filtrates with lytic activity of at least 10-4 according to Appelman concerning test strains and isolated bacterial isolates, as well as target additives in an amount of 0.01±99.99 wt % of composition weight. At that, Staphylococcus aureus phagolysate filtrate obtained using the Staphylococcus aureus SCH1 bacteriophage strain, deposited in the collection of FBIS SSC PVB of Rospotrebnadzor under number Ph-105, Staphylococcus aureus phagolysate filtrate obtained using the Staphylococcus aureus SCH111 bacteriophage strain, deposited in the collection of FBIS SSC PVB of Rospotrebnadzor under number Ph-95, Klebsiella pneumoniae phagolysate filtrate, obtained using the Klebsiella pneumoniae KPV15 bacteriophage strain, deposited in the collection of FBIS SSC PVB of Rospotrebnadzor under number Ph-90, Klebsiella pneumoniae phagolysate filtrate, obtained using the Klebsiella pneumoniae KPV811 bacteriophage strain, deposited in the collection of FBIS SSC PVB of Rospotrebnadzor under number Ph-91, Pseudomonas aeruginosa phagolysate filtrate, obtained using the PA5 Pseudomonas aeruginosa bacteriophage strain, deposited in the collection of FBIS SSC PVB of Rospotrebnadzor under number Ph-88, Pseudomonas aeruginosa phagolysate filtrate, obtained using the Pseudomonas aeruginosa PA10 bacteriophage strain, deposited in the collection of FBIS SSC PVB of Rospotrebnadzor under number Ph-89, Acinetobacter baumannii, phagolysate filtrate, obtained using the Acinetobacter Baumannii AM24 bacteriophage strain, deposited in the collection of FBIS SSC PVB of Rospotrebnadzor under number Ph-106. The composition version also contains Acinetobacter baumannii phagolysate filtrate, obtained using the Acinetobacter baumannii AP22 bacteriophage strain, deposited in the collection of FBIS SSC PVB of Rospotrebnadzor under number Ph-42. The appropriate bacteriophage strains are also proposed. Nucleic acid molecules corresponding to the genome of the said bacteriophages are also proposed.EFFECT: expanded range of products containing highly selective natural antibacterial components as the main active ingredient, ensured biological stability and activity of bacteriophages in the agent composition, the composition has a low risk of toxic and side effects, allows to expand versions and methods of practical application of the agent containing bacteriophages, provides storage stability and application efficiency over a wide temperature range.28 cl, 1 dwg, 4 tbl, 24 ex

Single-chemical nucleic acid molecules for gene expression control // 2628311
FIELD: biotechnology.SUBSTANCE: invention relates to biochemistry, in particular to a single-stranded nucleic acid molecule that inhibits target gene expression. The said molecule in the order from the 5'-end to the 3'-end contains the 5'-end portion Xc, the linker portion Lx, the inner portion Z, the linker portion Ly and the 3'-end portion Yc. At that, the inner region Z consists of the inner 5'-end portion X that is complementary to the 5'-end portion Xc and the inner 3'-end portion Y that is complementary to the 3'-end portion Yc. At that, Z consists of 19-30 bases and contains a sequence that suppresses the target gene expression. Z-(Xc+Yc) from 0 to 4 bases, Xc from 1 to 11 bases and Yc from 1 to 11 bases. This invention also discloses a method, application and composition for target gene expression inhibition, method, use and pharmaceutical composition for treatment of a disease caused by an increase in target gene expression using the above-mentioned nucleic acid molecule and the use of such molecule to induce RNA interference.EFFECT: invention allows application of a single-stranded nucleic acid molecule for patients treatment, since it does not cause a side effect in the form of interferon induction.32 cl, 32 dwg, 7 tbl, 25 ex

ethod for recombinant polypeptide production // 2628310
FIELD: pharmacology.SUBSTANCE: method for antibody production, a method for production of a pharmaceutical preparation containing an antibody obtained by this method, a nucleic acid molecule, application of a vector containing such nucleic acid molecule, and application of a cell where the said nucleic acid molecule or vector is artificially introduced in the method for antibody production. This method for antibody production involves culturing a cell that expresses an antibody-enhancing sequence (APES) that has been artificially inserted into a cell and into which an exogenous DNA encoding the desired antibody was introduced to produce the desired antibody, and wherein APES is a nucleic acid molecule containing a nucleotide sequence that can bind to DNA or mRNA of NfkBia gene derived from a human, mouse, rat, or hamster by base pairing, and can suppress expression of the NfkBia gene.EFFECT: invention allows production of an antibody at a high level with suppression of NfkBia expression.16 cl, 29 dwg, 8 ex

Human antibodies to clostridium difficile toxins // 2628305
FIELD: biotechnology.SUBSTANCE: completely human antibodies that bind either to toxin A, or to toxin B Clostridium difficile, or both to toxin A and toxin B. Formulations containing these antibodies and methods for their application are also described. The antibodies of the present invention are useful for neutralisation of toxins from C. difficile, thus providing agents for treatment of disease and symptoms associated with C. difficile infection, including an agent for treatment of diarrhea or pseudomembranous colitis caused by C. difficile. Antibodies may also limit the severity and/or duration of the underlying disease or limit the amount, duration and/or severity of disease relapse or exacerbation due to the presence of C. difficile.EFFECT: antibodies of this invention may also be suitable for infection diagnosis.34 cl, 5 dwg, 10 tbl, 11 ex
ethod for clinically narrow pelvis prediction // 2628245
FIELD: medicine.SUBSTANCE: term of gestation is specifid for pregnant women on the eve of delivery. By means of ultrasonic examination, direct and transverse dimensions of the input plane, direct dimension of the narrow part, transverse dimension of the output plane of the small pelvis, angle of the lunar arc, frontal-occipital, biparietal dimensions and angle of fetal head extension are measured. The coefficient of clinical compliance K is calculated according to the claimed formula. With the coefficient less than 24, a clinically narrow pelvis is predicted.EFFECT: method allows to accurately predict a clinically narrow pelvis by evaluating the most significant indicators.1 tbl, 3 ex
ethod for fetus condition prediction against background of delivery stimulation // 2628242
FIELD: medicine.SUBSTANCE: location of the placenta in the uterine cavity is determined by ultrasound. Areas of the maximum longitudinal and cross section of the placenta, placenta thickness, uterine myometrium thickness, diameter of the maximum cross section of the uterine cavity are determined. Fetal resistance coefficient R is calculated by the formula: , where S1 is the area of the maximum longitudinal section of the placenta (cm2), S2 is the cross-sectional area of the placenta (cm2), H is the placenta thickness (cm), D is the diameter of the maximal cross section of the uterine cavity (cm), T is the uterine myometrium thickness (cm), P is the index of placenta location in the uterine cavity, equal to 10.0 in case of placenta localization along the posterior wall and/r the left rib of the uterus, 10.5 in case of localization along the back wall and the right rib of the uterus, 11.0 in case of localization along the front wall and the left rib of the uterus, 11.5 in case of localization along the front wall and the right rib of the uterus, 12.0 in case of localization in the left corner or on the right rib of the uterus, 12.5 in case of localization in the uterus bottom, 13.0 in case of localization in the right corner of the uterus. If fetal resistance coefficient R is less than 2.0, fetus condition deterioration against the background of delivery stimulation is predicted.EFFECT: increased accuracy of prediction of fetus condition against the background of delivery stimulation.3 ex
ethod for estimation of fetal functional state in second pregnancy trimester by cardiotocography // 2628240
FIELD: medicine.SUBSTANCE: cardiac tachographs are analyzed with the determination of heart rate characteristics and selection of one of the three types of cardiotachograms corresponding to the fetal conditions: normal, suspicious and pathological. In this case, the evaluation is carried out in the second trimester of pregnancy in terms of: short-term heart rate variability, long-term heart rate variability, high variability episodes, low variability episodes, and deceleration episodes. The criterion for the normal type of fetal cardiotachogram is simultaneous achievement of the following normal values of the indices: short-term heart rate variability - at least 3.5 ms, long-term heart rate variability - at least 37 ms, high variability episodes - more than 5 min, low variability episodes - no more than 4 min, deceleration episodes - no more than 3. The criterion for the suspicious type of fetal cardiotachogram is a deviation of at least one of the indicators: high variability episodes, low variability episodes, and deceleration episodes from the normal value. The criterion for the pathological type of cardiotachogram is detection of at least one of the following conditions: deviation from normal short-term heart rate variability; deviation from normal long-term heart rate variability; simultaneously, high variability episodes are less than 5 minutes, low variability episodes are more than 5 minutes, deceleration episodes are more than 3 minutes; at the same time, high variability episodes amount to 0, low variability episodes are more than 5 minutes, and deceleration episodes are more than 3 minutes.EFFECT: method allows to predict and reveal fetal pathologies associated with placental insufficiency in the second trimester of pregnancy with high accuracy.30 ex

ethod for mammoplasty // 2628238
FIELD: medicine.SUBSTANCE: mammary gland (MG) plasty with high ptosis or a stretched "dermal sheath" is performed. At that, Botox is injected into the large pectoral muscle 8-10 days before the operation and into the cavity in the large pectoral muscle base during the operation, prior to implant insertion. During the operation, the MG skin within the operating field is shrunk by exposure to laser radiation or ultrasound. Fibrin glue mixed with a solution of a nonpolarizing muscle relaxant is used, and the cavity is washed with an antibiotic solution before drying.EFFECT: method has a high aesthetic effect, ensures the stability of the mammary gland with the necessary shape, minimizes ptosis, excludes scars on the incision site.3 cl, 14 dwg, 3 tbl, 3 ex
Piperazino[1,2-a]indole-1-ones and [1,4] diazeptino[1,2-a]indole-1-one // 2628126
FIELD: medicine.SUBSTANCE: invention relates to application of compounds of general formula I .EFFECT: new compounds, as well as pharmaceutical compositions based thereon, are obtained, that can be used to treat schizophrenia, obsessive-compulsive personality disorder, major depression, bipolar disorder, anxiety disorders, normal aging, epilepsy, retinal degeneration, traumatic brain injury, spinal cord injury, post traumatic stress disorder, panic disorder, Parkinson's disease, dementia, Alzheimer's disease, mild cognitive impairment, chemotherapy-induced cognitive dysfunction, Down's syndrome, autism spectrum disorders, hearing loss, tinnitus, spinocerebellar ataxia, amyotrophic lateral sclerosis, multiple sclerosis, Huntington's disease, stroke, and violations resulting from radiation therapy, chronic stress or abuse of neuroactive drugs, such as alcohol, opiates, methamphetamine, phencyclidine or cocaine.11 cl, 1 tbl, 46 ex

Cats calicivirus ashley virus strain for study of drug antiviral activity related to cats calicivirus // 2628096
FIELD: biotechnology.SUBSTANCE: ashley strain off cats calicivirus, deposited in FBIS SSC VB Vector under the number V-697 is obtain, having stable infectious activity, adapted to the transplanted cell cultures.EFFECT: strain can be used to study the antiviral activity of drugs against cats calicivirus.6 dwg, 4 ex

Rsv-specific binding molecules and means for their obtaining // 2628095
FIELD: biotechnology.SUBSTANCE: isolated antibody or a functional part thereof, capable of specifically binding the respiratory syncytial virus (RSV), is proposed. A nucleic acid molecule encoding the antibody is also provided. An expression vector and isolated cells comprising the said nucleic acid molecule for production of said antibody are described. In addition, the invention relates to a method for production of the said antibody, as well as to application of the said antibody in methods for RSV-related disorder treatment or prevention.EFFECT: invention allows to effectively bind RSV and can be used for RSV-related disorders therapy.27 cl, 16 dwg, 2 tbl, 5 ex

Antibodies, capable of specific connecting with her2 // 2628094
FIELD: biotechnology.SUBSTANCE: human epidermal growth factor 2 (HER2) receptor antibody is proposed, as well as pharmaceutical compositions comprising the said antibody for malignant tumour prevention and treatment and for apoptosis induction. In addition, a kit for malignant tumour diagnosing, comprising the said antibody, is provided.EFFECT: invention allows cancer cells destruction with significantly increased cytotoxicity when used in combination with trastuzumab and can be used for cancer therapy.11 cl, 27 dwg, 10 tbl, 15 ex
ethod for obtaining of msc-associated non-differentiated hemopoietic precursor cells with cd34+/cd133+ phenotype // 2628092
FIELD: biotechnology.SUBSTANCE: invention relates to production of cell cultures enriched with hematopoietic precursor cells with CD34+/CD133+ phenotype. The method includes preparation of a stromal sublayer, addition of an umbilical cord fraction, cultivation and selection. Multipotent stromal cells of adipose tissue (MSC) are obtained from the stromal-vascular fraction of adipose tissue, which are cultured at an O2 concentration of 5% in the environment. Mononuclear fraction of umbilical cord blood (MNF UB) is added to the MSC monolayer. After cocultivation, the undifferentiated hematopoietic precursors are selected from the mononuclear fraction of UB by adhesion to MSC at 20% O2, MSC is continued to be cultured with attached MNF UB for 96 hours at O2 concentration of 20% in the environment.EFFECT: invention allows to obtain a population enriched with undifferentiated hematopoietic umbilical cord blood precursors with this complex phenotype.9 dwg, 1 tbl, 1 ex

Immunocytocins combined therapy // 2628089
FIELD: pharmacology.SUBSTANCE: method for skin tumor treatment by TNF immunoconjugate single dose injectionα and IL-2 immunoconjugate single dose to tumor localization site, at that, injectable administration of TNF immunoconjugateα and IL-2 immunoconjugate is carried out simultaneously. TNF immunoconjugateα contains TNFα, bound to an antibody molecule that binds to the additional ED-B domain of the B-FN fibronectin splice isoform. The IL-2 immunoconjugate comprises IL-2, bound to an antibody molecule that binds to the additional ED-B domain of the B-FN fibronectin splice isoform. The invention also relates to compositions for skin tumor treatment comprising the said TNF immunoconjugateα and/or the said IL-2 immunoconjugate.EFFECT: invention provides for stimulation of complete destruction of large subcutaneous tumors with a single local administration of a combination of TNF immunoconjugateα and IL-2 immunoconjugate.42 cl, 4 dwg
Pyperidinyl naphthyluxic acids // 2628083
FIELD: pharmacology.SUBSTANCE: invention relates to compounds of formula (I): , as well as to pharmaceutically acceptable salts, pharmaceutical compositions and application thereof.EFFECT: new compounds that are CRTH2 receptor antagonists have been obtained that can be useful for respiratory diseases treatment or prevention.20 cl, 2 tbl, 37 ex
Hinuclidine ethers of 1-azaheterocylic acetic acid as antimuscarine means, method for their production and their drug compositions // 2628082
FIELD: pharmacology.SUBSTANCE: invention relates to formula compounds, where A can be a single bond, a double bond, O, S, NR3, C(R3)R4, CO, C(O)N(R3), N(R3)C(O) and C(R3)-(CH2)-C(R4); m is an integer from 1 to 4; N is 0 or an integer from 1 to 4; R1 is selected from the group consisting of phenyl and 5-member heteroaryl containing one S heteroatom optionally substituted by one or more substituents selected from the group consisting of halogen atoms, (C1-C6)alkyl and (C1-C6)alkoxy; X is a physiologically acceptable anion; R2 is a group of the formula (Y), where p is 0 or an integer from 1 to 4; Q is 0 or an integer from 1 to 4; P is absent or selected from the group consisting of CO, N(R3)C(O) and C(O)N(R3); W is selected from the group consisting of H, (C1-C10)alkoxyl, phenyl, heteroaryl optionally substituted with one or more substituents selected from the group consisting of halogen atoms, OH, oxo (=O), CO2R3, (C1-C6)alkyl, (C1-C6)alkoxyl and phenyl; wherein heteroaryl is a mono- or bicyclic ring system having from 5 to 9 ring atoms and from 1 to 3 heteroatoms selected from N, O and S; R3 and R4 are independently selected from the group consisting of H, halogen atoms, CONH2, (C1-C6)alkyl, (C1-C6)alkanoyl and (C3-C8)cycloalkyl, as selective M3 receptor antagonists, to a method for their preparation, to compositions containing them, and to their therapeutic use for treatment of a respiratory disease such as asthma and chronic obstructive pulmonary disease (COPD).EFFECT: increased composition application efficiency.14 cl, 2 tbl, 34 ex

New derivative of 3-(4-(benzyloxy)phenyl)hex-4-ine acid, method for its production and pharmaceutical composition for metabolic disease prevention and treatment including it as effective ingredient // 2628077
FIELD: pharmacology.SUBSTANCE: invention relates to a compound represented by formula 1, its optical isomer or a pharmaceutically acceptable salt thereof: [Formula 1] , as well as to methods for its preparation and a pharmaceutical composition based on it.EFFECT: new connections are obtained, with the ability to activate the GPR40 enzyme, suitable for use for metabolic disease prevention or treatment.10 cl, 7 tbl, 77 ex, 2 dwg
Tricyclic nitrogen-containing derivatives of imidazo[4,5-c]pyridine, having inhibiting activity in response to hystamine 4 receptor (hh4r) // 2628074
FIELD: pharmacology.SUBSTANCE: invention relates to a heterocyclic compound of formula 1 , or to a racemate, isomer, or pharmaceutically acceptable salt thereof, wherein X1 and X2 are C; each of X3 and X4 is independently C or N, provided that one of X3 and X4 is N; R1 is a saturated 4-9 member mono- or bi-heterocyclyl containing 1-2 heteroatoms (where the heteroatoms are N), where R1 is unsubstituted or substituted by 1 to 3 substituents selected from -NR6R7 and R8; or R1 is selected from -NR6R7 and R8; R2, R3, R4 and R5 may be the same or different; and each is independently selected from -H; -C1-C6alkyl; -C1-C6haloalkyl; -C1 -C6perhaloalkyl; -halogen (-F, -Cl, -Br, -I); -CN; -C1-C6talkoxy; -C1-C6haloalkoxy; -C1-C6perhaloalkoxy; C2alkenyl; -C2-C3alkynyl; -amino; -OH; -nitro (-NO2); -C6-C1aryl; and furan; provided that, when X3 is N, R4 is absent; and when X4 is N, R5 is absent, each of Y1, Y2, Y3, Y4 and Y5 is independently C or a heteroatom (preferably a heteroatom independently selected from N, O and S), provided that at least two of Y1, Y2, Y3, Y4 and Y5 are heteroatoms independently selected from N and O; each of Y2 and Y3 can be independently substituted by R9; Y4 may be substituted with -H or -C1-C6alkyl; each of R6 and R7 is independently selected from -H; -C1-C6alkyl; and -carboxyl (-COOH); R8 is -C1-C6alkyl or -C3cycloalkyl; and R9 is selected from -H; -C1-C6alkyl; and -C3cycloalkyl; wherein the alkyl and heterocyclyl may be independently unsubstituted or substituted by one or more substituents (for example, 1 to 3 substituents) selected from the group consisting of -C1-C4alkyl, -C1-C4alkoxy and -OH. The invention also relates to particular compounds and a pharmaceutical composition based on the said compounds.EFFECT: new heterocyclic compounds useful for human histamine receptor 4 inhibition are obtained.13 cl, 13 tbl, 144 ex

New cc-1065 analogs and their conjugates // 2628069
FIELD: pharmacology.SUBSTANCE: invention relates to a compound of formula or a pharmaceutically acceptable salt thereof, wherein DB is a DNA-binding group and is DB6 group ; R1 is chlorine; R2, R2', R3, R3', R4, R4', R12 and R19are H; X2 is selected from C(R14)(R14'), where R14' has the same value as defined for R7' and is independently selected, and R14' and R7' are absent, which gives a double bond between the atoms carrying R7' and R14'; R5, R6 and R7 are independently selected from H, R, where Re are selected from C1Alkyl, and R5'+R6', are absent, which gives a double bond between the atoms carrying R5 and R6, and/or R6 and R7, and/or R7 and R14 respectively; X1 is selected from O; X3 is selected from S, N, and NR15; X4 is selected from N and CR16; X5 is selected from O; X6* is selected from CR11; X7 is selected from CR8, N; X8 is selected from CR9, N; X9* is selected from CR10; X10* is selected from CR20; X11* is selected from C; X7* and X8* have the same values as those defined for X7 and X8 respectively, and are chosen independently; X34 is selected from C; annular atom B in X11* in DB6 is connected to the ring atom of ring A, so that ring A and ring B in DB6 are directly connected through a direct link; fig. implies that the said bond can be a or a non-cumulated direct bond, optionally delocalized, double bond; R8, R9, R10, R11, R15, R16, R20 are each independently selected from H, N(Rh)C(O)Ri, where Rh, Ri are independently selected from H and optionally substituted C6 aryl, one optional substituent in Ri is -OH or -NH2; a is 0 and b is 1. The invention relates to a pharmaceutical composition for tumour treatment or prevention for a mammal, comprising a therapeutically effective amount of formula (I) compound and a pharmaceutically acceptable carrier.EFFECT: DNA-alkylating agent SS-1065 analogues.6 cl, 13 dwg, 1 tbl, 23 ex
ethod for diagnosis of lower jaw mobility and device for its implementation // 2628064
FIELD: medicine.SUBSTANCE: group of inventions includes a device for diagnosis of movements and forces of the lower jaw dentition relative to the upper jaw dentition and a method of diagnosis using the device, refers to the field of medicine and can be used in dental practice. The device for diagnosis of movements and forces of the lower jaw dentition relative to the upper jaw dentition contains a carrier fastened to the dentition or on the tooth or on a dental structure or inside a dental structure or on the gum, and on which at least one sensor is located for real-time registration of the investigated parameter associated with lower jaw functioning, as well as an electronic unit with the function of obtaining measurement data and their processing, a power unit and unit for measurement data transmission to the external receiving computerized means. The carrier is made in the form of a flexible or rigid plate, on which the electronic unit in the form of a microprocessor, a measurement data transmission unit made in the form of a process connector for wire communication or a wireless communication module, and a sensor or sensors made with different functions for measurement of the investigated parameters are fixed, and a power supply made in the form of at least one battery, or a wired power module or a wireless power module, is located next to the carrier, mechanically associated with it and electrically connected to the components on the carrier. The method for diagnosis of movements and forces of the lower jaw dentition relative to the upper jaw dentition is performed by the device.EFFECT: possibility of obtaining a reliable picture of movements and efforts of the lower jaw dentition relative to the upper jaw dentition to obtain a diagnosis and choose a method of treatment.8 cl, 4 dwg

Improved stretch elastomer pump for the infusion system // 2628062
FIELD: medicine.SUBSTANCE: elastomeric pump for the infusion unit contains a central rod with a cylindrical body and a stretchable elastomeric tube. The cylindrical body has a first end and an opposing second end, a length, a constant outer diameter defining the first radius, a central channel extending along the entire length of the rod, a first port located between the first end and the second end and extending from the outer diameter to the central channel, for the fluid, a fill port located at the first end and communicating with mentioned channel and an output port located at the second end and communicating with mentioned channel. A stretchable elastomeric tube is disposed around a central rod between its first and second ends and coaxially with the overlapping of the first port. The tube is sealed to the central rod at its ends and has an initial internal diameter defining a second radius corresponding to the first radius, length, which is less than the length of the central rod, and the wall thickness, chosen taking into account the second radius. The variants of performing the pump, differing in the characteristics of the elastomeric tube, are disclosed.EFFECT: providing long-term outpatient administration of pharmaceutical fluids at a controlled rate.14 cl, 8 dwg, 11 tbl
System for treatment of the ras // 2628061
FIELD: medicine.SUBSTANCE: method for the therapeutic treatment of wounds on the human or animal body includes a first stage of treatment in which low-pressure wound therapy is performed with a reduced pressure device and a second stage of treatment that is performed using a wound dressing without creating a low pressure in a humid environment. The wound dressing has absorbent elements containing a swelling polymer. The low-pressure treatment device comprises an airtight covering material for sealing the wound and the area around the wound where the wound space will be formed, means for providing fluid communication between the wound space and the externally provided source of reduced pressure covered with the coating material, such that in the wounded space A low pressure is established, and the fluid exits the wounded space, a wound dressing that contributes, in essence, Uniform distribution of low pressure in the wound space.EFFECT: improving the treatment of wounds in terms of its cost without affecting clinical efficacy and improving its clinical effectiveness.11 cl, 4 dwg
Conductor catheter for laser adenotomy with transoral access, set of conductor catheters and method for laser adenotomy with transoral access // 2628060
FIELD: medicine.SUBSTANCE: conductor catheter for laser adenotomy by transoral access is made in the form of a rubber tube with Shore A-120 hardness, which is curved along the anatomical structure of the nasopharynx and has a straight working end of 10-40 mm, oriented at an angle of 85-145° to its longitudinal axis. The end part of the working end is designed to guide and position the surgical laser light guide at the pole of the nasopharyngeal tonsil. A set of conductor catheters for laser adenotomy by transoral access, containing three catheter-conductors intended for the lower, middle or upper poles of the nasopharyngeal tonsil, is developed. The method for laser adenotomy by transoral access involves laser vaporization of adenoid vegetations, with lymphoid tissue being removed from the bottom up using a set of developed conductor catheters.EFFECT: possibility of laser radiation delivery to the nasopharyngeal tonsil by a transoral route, laser vaporization of the adenoid tissue from hard-to-reach areas.8 cl, 1 dwg

Construction of multifocal lens and method of prevention and/or decommission of progratization of myopia // 2628059
FIELD: physics.SUBSTANCE: group of inventions concerns contact lenses incorporating multifocal optical power profiles that perform at least one of the actions - slowing, restraining or preventing the progression of myopia. Such a lens comprises a first zone in the center of the lens and at least one peripheral zone surrounding the first region. At least one peripheral zone has a different thickness and optical power than the first region. The first zone and at least one peripheral zone are stepped or jagged.EFFECT: multifocal optical force profile provides an essentially equivalent foveal vision correction provided by a single focal lens and has such a depth of focus and a reduced sensitivity to CI that slows down, inhibits or prevents the progression of myopia.26 cl, 3 tbl, 8 dwg

Integrated access to multiple clinical data analysis modules and integration with these modules // 2628058
FIELD: medicine.SUBSTANCE: system of analytical tools integration for user direction during analytical tools set (24) applicatio contains: an end machine (22), a local storage device (36) for patient-dependent information, graphical user interface module (16) in conjunction with the end machine. The end machine also contains a table (32) of state transition parameters and a table (34) of change or detail view parameters for each state, which stores state specified parameters (SSP), created for the clinical context, and user-definable parameters (UDP) to input in one or more of the available analytical tools. The end machine and GUI module contain an electronic device (10) for data processing, including a graphical display (12) and at least one user input device (14). The current clinical context defined by the patient-dependent information available through the end machine is stored. One or more available analytical tools that apply to the current state are idendified. One or more parameters from the state transition parameter table, change or detail view parameter table and the local storage device is downloaded to the user-selected available analytical tool. The user-selected available analytical tool is activated. The transition from the current state to the next state, containing clinical context defined by the available patient-dependent information that includes additional patient-dependent information in accordance with the state transition parameter table of the end machine is performed.EFFECT: group of inventions allows efficient user direction and analytical tools application, timely patient data submission by integrating the system with the available analytical tools, as well as availability of a state transition parameter table and parameter change and detail view table for each state.14 cl, 12 dwg

Catheter clutch // 2628057
FIELD: medicine.SUBSTANCE: catheter clutch comprises a tubular portion and two clamping jaws, namely a main clamping jaw and a clamping jaw on the hinge extending in the longitudinal direction of the tubular portion and forming a channel together with the tubular portion. The channel has an opening for catheter end portion location when the clamping jaws abut each other. The clamping jaws are interconnected at the corresponding end of the clamping jaws by the clamping jaws hinge having a hinge axis extending transversely to the tubular portion. The other ends of the clamping jaws in each case are provided with a snap-in locking element and a snap-in locking counter-piece, respectively, cooperating with each other to form a snap-in locking device. The tubular part is deformable by at least one deformation part for secure positioning of the catheter end portion when the snap-in locking device is in an engaged position. The catheter clutch comprises at least one viewing window formed between the clamping jaw on the hinge on one side and the main clamping jaw on the other side and providing visual inspection of the stopping place of the catheter end portion in the tubular portion.EFFECT: easy to use.10 cl, 5 dwg
ethod for laparoscopic left-sided lateral liver sectorectomy // 2628056
FIELD: medicine.SUBSTANCE: at laparoscopic left-sided lateral liver sectorectomy, the left hepatic artery, the left branch of the portal vein, is circularly isolated from the donor after liver left lobe mobilization. A line of resection is marked on the diaphragmatic surface of the liver 3-5 mm to the right from the crescent ligament of the liver. 2-4 cm2 of the liver parenchyma is separated along the intended line. LLS is rotated. 0.5-1 cm2 of the liver parenchyma is separated along the boundary between the lower and middle thirds of the furrow between the caudate lobe of the liver and the LLS. Dissector branches are introduced into the formed hole. On the side of the diaphragmatic liver surface, ends of two ribbons are captured by the dissector and removed from the visceral surface of the liver. Liver parenchyma with a portal plate is suspended on the first ribbon. Liver parenchyma with the left hepatic vein is suspended on the second ribbon. Then, the liver parenchyma is separated along the resection planes by the first and second braid. The portal plate is cut, the left hepatic artery, the left branch of the portal vein, is clipped and crossed, stitched with a hardware suture, and the left hepatic vein is crossed. The transplant is taken from the abdominal cavity.EFFECT: method allows to simplify the technique of liver parenchyma separation for prevention of biliary and vascular complications.5 cl, 4 dwg

ethod to use the auxiliary channel to achieve rapid and effective according to the power joining in the wireless networks // 2628055
FIELD: radio engineering, communication.SUBSTANCE: for wireless patient data transmission use one or more MBAN devices, that implement the patient data transfer to the concentrator device through the short-range wireless communication, at that the patient data transfer through the short-range wireless communication is performed within the predetermined range. The concentrator device receives the patient data, transmitted from the mentioned one or more MBAN devices and provide communication with the central monitoring station by means of the longer-range communication. The mentioned one or more MBAN devices transmit the joining request to the concentrator device through one or more auxiliary channels, to attach each MBAN device to the MBAN system. Auxiliary channels are located outside the predetermined spectrum.EFFECT: group of inventions enables to provide rapid and effective according to the power joining to the wireless networks, eliminate the chance of losing the critical medical data, to improve the efficiency, safety and medical and sanitary works result.15 cl, 8 dwg

Staple cartridge, including crushable plate // 2628054
FIELD: medicine.SUBSTANCE: end effector of the surgical stapler includes an abutment, wherein the end effector includes a staple cartridge. The staple cartridge contains a plate, a plurality of staples, a crushable tissue thickness compensator, and a supporting surface of the staple cartridge. The plate has a surface and a plurality of apertures passing through the plate. Each staple has a base and at least two legs protruding from the base, with the legs at least partially protruding into the apertures. The crushable tissue thickness compensator is located above the surface of the plate, while the tissue thickness compensator has a surface in contact with tissues. The support surface of the staple cartridge is designed to support the staple bases. The plate is slidable downwards, towards the support surface of the staple cartridge by the pushing action of the abutment for legs deformation. The staple cartridge for use with a surgical stapler including an abutment, wherein the cartridge includes a plate, a plurality of staples, and a crushable tissue thickness compensator. The plate is slidable downwards in the direction of the bases between the inoperative position and the actuation position by the pushing force of the surgical stapler abutment for legs deformation. For the second version, a staple cartridge for use with a surgical stapler including an abutment, wherein the cartridge comprises a plate and a plurality of staples. Each staple has a base and at least two legs protruding from such a base. The legs at least partially enter the apertures, and the plate can be crushed in the direction of such bases between the inoperative position and the operating position when the staple legs are deformed by the surgical stapler abutment.EFFECT: inventions provide compensation for various tissue thicknesses clamped in different staples.19 cl, 408 dwg
 
2551048.
Up!